Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Oncol Pharm Pract ; 24(5): 389-392, 2018 Jul.
Article in English | MEDLINE | ID: mdl-28355971

ABSTRACT

Pembrolizumab, a selective anti-PD-1 humanized monoclonal antibody, reactivates T cells to fight cancer. Immune-related adverse events such as autoimmune colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis may occur during, or weeks to months after therapy. Pemprolizumab-induced synovitis is rarely reported. With the wide use of immunotherapy to treat cancers, physicians need to be aware of this rare immune-related adverse event and provide immediate treatment to avoid permanent joint damage.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents/adverse effects , Synovitis/chemically induced , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Agents/therapeutic use , Female , Humans , Immunotherapy , Melanoma/drug therapy , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...